Respiratory Microbiota and Immune Response in CVID

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-15

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency. Respiratory ailments are the most frequent complications of CVID, with chronic pulmonary disease developing in 30-60% and even more experiencing frequent acute respiratory infections. This project aims to establish cutting-edge approaches to study pulmonary biology in CVID and apply novel bioinformatics strategies to study complex interactions among microbes and host cells by direct sampling of the respiratory tract. The central hypothesis for this research is that antibody (Ab) deficiency in CVID alters respiratory microbiota and host interactions to drive pulmonary disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lymphocyte Immunophenotyping in Common Variable Immunodeficiency

NCT01196702

Common Variable Immunodeficiency Granulomatous Disease Bronchiectasis +1 more

COMPLETED

Lung Innate Immunity and Microbiome After Tuberculosis Exposure

NCT06526689

Tuberculosis Latent Tuberculosis

RECRUITING

Integrated Discovery and Development of Innovative TB Diagnostics

NCT06624501

Tuberculosis, Pulmonary

COMPLETED

Tuberculosis Immunity in Children

NCT00170638

Tuberculosis

COMPLETED

Characterization and Evaluation of Diagnostic Biomarkers for Tuberculosis

NCT01269268

Active Tuberculosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CVID

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Antibody deficient participants

Provider referred patients that have antibody deficiency.

No interventions assigned to this group

Controls

Patients without antibody deficiency from the allergy and immunology clinic at Boston Medical Center and from healthy volunteers at the BU School of Medicine.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with primary antibody deficiency diagnosed by their treating physician
* Controls will not have a diagnosis of immunodeficiency of any sort
* Male and female patients will be enrolled evenly

Exclusion Criteria

* Patients who self identify as pregnant
* Patients with asthma or chronic obstructive pulmonary disease (COPD) that are not well controlled clinically

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes